IMR Press / FBL / Volume 20 / Issue 7 / DOI: 10.2741/4365

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

MMP Inhibitors: Past, present and future
Show Less
1 Department of Pharmacology, Stony Brook University, Stony Brook, NY 11794, USA
2 Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA
Front. Biosci. (Landmark Ed) 2015, 20(7), 1164–1178;
Published: 1 June 2015

Development of inhibitors of (MMPs) has been fraught with challenges. Early compounds largely failed due to poor selectivity and bioavailability. Dose-limiting side effects, off-target interactions, and improperly designed clinical trials significantly impeded clinical success. As information becomes available and technology evolves, tools to combat these obstacles have been developed. Improved methods for high throughput screening and drug design have led to identification of compounds exhibiting high potency, binding affinity, and favorable pharmacokinetic profiles. Current research into MMP inhibitors employs innovative approaches for drug delivery methods and allosteric inhibitors. Such innovation is key for development of clinically successful compounds.

Matrix Metalloproteinases
MMP inhibitor
Back to top